Your browser doesn't support javascript.
loading
A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression.
Zhao, Huajun; Shao, Xianyu; Yu, Yating; Huang, Lulu; Amor, Narh Philip; Guo, Kun; Weng, Changzhen; Zhao, Weijun; Yang, Ailu; Hu, Jiesen; Yang, Hongbao; Liu, Zhenguang; Han, Qiuju; Shi, Leilei; Sun, Shiyu; Zhang, Jian; Lin, Ang; Yang, Yong.
Afiliación
  • Zhao H; Institute of Immunopharmaceutical Sciences, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, China. zhaohuajun89@sdu.edu.cn.
  • Shao X; Vaccine Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Yu Y; Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing, China.
  • Huang L; Institute of Immunopharmaceutical Sciences, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, China.
  • Amor NP; Vaccine Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Guo K; Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing, China.
  • Weng C; Vaccine Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Zhao W; Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing, China.
  • Yang A; Vaccine Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Hu J; Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing, China.
  • Yang H; Vaccine Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Liu Z; Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing, China.
  • Han Q; Vaccine Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Shi L; Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing, China.
  • Sun S; Institute of Immunopharmaceutical Sciences, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, China.
  • Zhang J; Firestone Biotechnologies, Shanghai, China.
  • Lin A; Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing, China.
  • Yang Y; College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, China.
NPJ Vaccines ; 9(1): 22, 2024 Feb 03.
Article en En | MEDLINE | ID: mdl-38310094
ABSTRACT
Here we report on the development and comprehensive evaluations of an mRNA vaccine for chronic hepatitis B (CHB) treatment. In two different HBV carrier mouse models generated by viral vector-mediated HBV transfection (pAAV-HBV1.2 and rAAV8-HBV1.3), this vaccine demonstrates sufficient and persistent virological suppression, and robust immunogenicity in terms of induction of strong innate immune activation, high-level virus-specific antibodies, memory B cells and T cells. mRNA platform therefore holds prospects for therapeutic vaccine development to combat CHB.
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: NPJ Vaccines Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: NPJ Vaccines Año: 2024 Tipo del documento: Article